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background:  Emerging evidence suggests in-stent neoatherosclerosis (NA) as an important mechanism for late stent failure. Although 
statin therapy has been shown beneficial for native vessel atherosclerosis, whether it prevents or delays NA is unknown.
methods:  We identified 211 patients with 251 stents who underwent follow-up OCT imaging. NA was defined as the presence of lipid-
laden intima or calcification inside neointima. All stents were divided into the two groups: on statin therapy (n=205) and not on statin 
therapy (n=46). The reasons for not being on statin were intolerance or contraindications. The quantitative and qualitative characteristics of 
neointimal hyperplasia (NIH) were compared between the two groups within early phase (<1year) and late phase (≥1year).
Results:  In late phase, stents in the statin group had significant thinner NIH (350±191 µm vs. 491±237 µm, p=0.008), lower incidence of 
NA (p=0.037), lipid-laden intima (p=0.012), and macrophage (p=0.001) compared to those in non-statin group (Figure A). In early phase, 
however, these differences were not significant between the two groups (Figure B, all p>0.05). The incidences of in-stent thrombus, 
disruption, and calcification were similar between the two groups regardless of stent duration. After adjusting for stent duration, stent type, 
and risk factors in multivariate model, statin use was independently associated with lower incidence of NA.
conclusion:  Statin therapy appears to decrease the NIH and the development of NA.
 
